Fares Qeadan
Fares Qeadan is a researcher at Loyola University Chicago who has contributed to the discussions around the potential use of GLP-1 medications in treating substance addiction. His insights emphasize the significance of these findings for health professionals, suggesting that the results could influence prescribing practices for metabolic conditions.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Guatemala | 1 | 7.00 | 0.18% | +0% | 17,915,568 | 31,597 | $82,000 | 145$ |
| Switzerland | 1 | 6.00 | 0.17% | +0% | 8,654,622 | 14,376 | $700,000 | 1,163$ |
| Totals | 2 | 26,570,190 | 45,973 | $782,000 | 1,308$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Fares Qeadan from the Parkinson School of Health Sciences and Public Health in Chicago comments on the need for more evidence before prescribing Ozempic to all addiction patients.
6
Guatemala:
Fares Qeadan notes that traditional treatments remain a priority, but these results should be considered by doctors when prescribing GLP-1 for metabolic reasons.
7